UCLA Study Traces How Statins May Aid Liver Cancer Prevention

Researchers Map Cellular Routes for Liver Cancer Prevention

Researchers at the University of California, Los Angeles have identified a cellular pathway that helps explain how statin medications could influence liver cancer prevention in metabolic dysfunction-associated steatotic liver disease (MASLD). The study, published in Hepatology Communications, examined how cholesterol-lowering drugs affect hepatic stellate cells located near primary liver tumors.

Previous observational studies linked statin use to lower rates of cirrhosis and primary liver cancer. The biological mechanisms driving that protective association remained unexplained before these laboratory experiments.

The Role of Hepatic Stellate Cells in Tumor Environments

Hepatic stellate cells help maintain the liver's physical structure but change their behavior in response to chronic injury. In patients with metabolic dysfunction-associated steatotic liver disease, these structural cells collect in tissue directly surrounding hepatocellular carcinoma tumors.

Cirrhosis does not always come first. Hepatocellular carcinoma represents the most common form of primary liver cancer, and the malignancy can develop in patients with metabolic liver disease even before cirrhosis occurs.

How Statins Alter the GGPP-Rho-YAP Signaling Axis

Statins suppress structural signaling by reducing levels of geranylgeranyl pyrophosphate (GGPP), an intermediate molecule that activates regulatory Rho GTPase proteins. Lower levels of geranylgeranyl pyrophosphate change the physical structure of hepatic stellate cells.

This structural change traps a signaling protein called YAP outside the cell nucleus. Kept outside the nucleus, the protein cannot switch on genes responsible for tissue remodeling around the tumor.

Restoring geranylgeranyl pyrophosphate reversed the effect during laboratory testing, confirming the specific molecular route. Tissue samples also showed increased expression of GGPS1, an enzyme that produces geranylgeranyl pyrophosphate, in cells bordering tumors.

Tissue Sequencing and Laboratory Testing Methods

The study team analyzed human liver tissue taken from patients who underwent liver resection or transplantation at the University of California, Los Angeles. Scientists applied single-nucleus RNA sequencing to map gene activity across distinct populations of hepatic stellate cells.

Spatial imaging then mapped where cells and YAP-related genes sat in relation to tumor margins. Follow-up experiments exposed cultured human hepatic stellate cells to statins in controlled laboratory conditions.

Current Limitations in Liver Cancer Prevention Research

These findings establish a biological mechanism in laboratory conditions but do not prove that statins prevent or treat liver cancer in human patients. The study authors emphasized that these results do not change how clinicians currently prescribe statin medications.

Patients managing metabolic liver conditions can discuss cardiovascular therapy and liver cancer prevention markers with their physician.